Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Combined Treatment With Exenatide and Cyclosporine A or Parstatin 1-26 Results in Enhanced Reduction of Infarct Size in a Rabbit Model.

Alexopoulos P, Panoutsopoulou K, Vogiatzis G, Koletsis E, Dougenis D, Tsopanoglou NE.

J Cardiovasc Pharmacol. 2017 Jul;70(1):34-41. doi: 10.1097/FJC.0000000000000492.

PMID:
28679129
2.

Highly functionalized 2-oxopiperazine-based peptidomimetics: an approach to PAR1 antagonists.

Valdivielso ÁM, Ventosa-Andrés P, Tato F, Fernández-Ibañez MÁ, Pappos I, Tsopanoglou NE, García-López MT, Gutiérrez-Rodríguez M, Herranz R.

Eur J Med Chem. 2013;70:199-224. doi: 10.1016/j.ejmech.2013.09.058. Epub 2013 Oct 10.

PMID:
24158013
3.

NGF promotes hemodynamic recovery in a rabbit hindlimb ischemic model through trkA- and VEGFR2-dependent pathways.

Karatzas A, Katsanos K, Lilis I, Papadaki H, Kitrou P, Lecht S, Marcinkiewicz C, Siablis D, Lelkes PI, Lazarovici P, Tsopanoglou NE.

J Cardiovasc Pharmacol. 2013 Sep;62(3):270-7. doi: 10.1097/FJC.0b013e3182982de7.

PMID:
23644989
4.

Design, synthesis and biological evaluation of new peptide-based ureas and thioureas as potential antagonists of the thrombin receptor PAR1.

Ventosa-Andrés P, Valdivielso AM, Pappos I, García-López MT, Tsopanoglou NE, Herranz R.

Eur J Med Chem. 2012 Dec;58:98-111. doi: 10.1016/j.ejmech.2012.10.015. Epub 2012 Oct 17.

PMID:
23123726
5.

Parstatin prevents renal injury following ischemia/reperfusion and radiocontrast administration.

Diamantopoulos A, Kyriazis I, Geronatsiou K, Papadaki H, Loudos G, Kagadis GC, Katsanos K, Liatsikos E, Karnabatidis D, Siamblis D, Tsopanoglou NE.

Am J Nephrol. 2012;36(3):278-86. doi: 10.1159/000341871. Epub 2012 Sep 7.

PMID:
22965158
6.

The protease-activated receptor 1 possesses a functional and cleavable signal peptide which is necessary for receptor expression.

Zampatis DE, Rutz C, Furkert J, Schmidt A, Wüstenhagen D, Kubick S, Tsopanoglou NE, Schülein R.

FEBS Lett. 2012 Jul 30;586(16):2351-9. doi: 10.1016/j.febslet.2012.05.042. Epub 2012 May 31.

7.

Parstatin suppresses ocular neovascularization and inflammation.

Huang H, Vasilakis P, Zhong X, Shen JK, Geronatsiou K, Papadaki H, Maragoudakis ME, Gartaganis SP, Vinores SA, Tsopanoglou NE.

Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5825-32. doi: 10.1167/iovs.10-5576. Epub 2010 Jun 10.

8.

Thrombin's central role in angiogenesis and pathophysiological processes.

Tsopanoglou NE, Maragoudakis ME.

Eur Cytokine Netw. 2009 Dec;20(4):171-9. doi: 10.1684/ecn.2009.0166. Review.

9.

Parstatin(1-26): the putative signal peptide of protease-activated receptor 1 confers potent protection from myocardial ischemia-reperfusion injury.

Routhu KV, Tsopanoglou NE, Strande JL.

J Pharmacol Exp Ther. 2010 Mar;332(3):898-905. doi: 10.1124/jpet.109.162602. Epub 2009 Dec 15.

PMID:
20008957
10.

Parstatin: a cryptic peptide involved in cardioprotection after ischaemia and reperfusion injury.

Strande JL, Widlansky ME, Tsopanoglou NE, Su J, Wang J, Hsu A, Routhu KV, Baker JE.

Cardiovasc Res. 2009 Jul 15;83(2):325-34. doi: 10.1093/cvr/cvp122. Epub 2009 Apr 20.

11.

Thrombin promotes arteriogenesis and hemodynamic recovery in a rabbit hindlimb ischemia model.

Katsanos K, Karnabatidis D, Diamantopoulos A, Kagadis GC, Ravazoula P, Nikiforidis GC, Siablis D, Tsopanoglou NE.

J Vasc Surg. 2009 Apr;49(4):1000-12. doi: 10.1016/j.jvs.2008.11.004. Epub 2009 Feb 14.

12.

Parstatin, the cleaved peptide on proteinase-activated receptor 1 activation, is a potent inhibitor of angiogenesis.

Zania P, Gourni D, Aplin AC, Nicosia RF, Flordellis CS, Maragoudakis ME, Tsopanoglou NE.

J Pharmacol Exp Ther. 2009 Feb;328(2):378-89. doi: 10.1124/jpet.108.145664. Epub 2008 Nov 6.

PMID:
18988770
13.

Thrombin mediates mitogenesis and survival of human endothelial cells through distinct mechanisms.

Zania P, Papaconstantinou M, Flordellis CS, Maragoudakis ME, Tsopanoglou NE.

Am J Physiol Cell Physiol. 2008 May;294(5):C1215-26. doi: 10.1152/ajpcell.00452.2007. Epub 2008 Mar 26.

14.

Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1.

Tsopanoglou NE, Maragoudakis ME.

Semin Thromb Hemost. 2007 Oct;33(7):680-7. Review.

PMID:
18000795
15.

Methylene blue inhibits angiogenesis in chick chorioallontoic membrane through a nitric oxide-independent mechanism.

Zacharakis N, Tone P, Flordellis CS, Maragoudakis ME, Tsopanoglou NE.

J Cell Mol Med. 2006 Apr-Jun;10(2):493-8.

16.

Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis.

Zania P, Kritikou S, Flordellis CS, Maragoudakis ME, Tsopanoglou NE.

J Pharmacol Exp Ther. 2006 Jul;318(1):246-54. Epub 2006 Apr 4.

PMID:
16595737
17.

Thrombin functions through its RGD sequence in a non-canonical conformation.

Papaconstantinou ME, Carrell CJ, Pineda AO, Bobofchak KM, Mathews FS, Flordellis CS, Maragoudakis ME, Tsopanoglou NE, Di Cera E.

J Biol Chem. 2005 Aug 19;280(33):29393-6. Epub 2005 Jul 5.

18.

On the mode of action of thrombin-induced angiogenesis: thrombin peptide, TP508, mediates effects in endothelial cells via alphavbeta3 integrin.

Tsopanoglou NE, Papaconstantinou ME, Flordellis CS, Maragoudakis ME.

Thromb Haemost. 2004 Oct;92(4):846-57.

PMID:
15467917
19.

Role of thrombin in angiogenesis: a rebuttal.

Maragoudakis ME, Tsopanoglou NE.

J Thromb Haemost. 2004 May;2(5):841-2; discussion 843. No abstract available.

20.

Role of thrombin in angiogenesis and tumor progression.

Tsopanoglou NE, Maragoudakis ME.

Semin Thromb Hemost. 2004 Feb;30(1):63-9. Review.

PMID:
15034798
21.
22.

On the mechanism of thrombin-induced angiogenesis: involvement of alphavbeta3-integrin.

Tsopanoglou NE, Andriopoulou P, Maragoudakis ME.

Am J Physiol Cell Physiol. 2002 Nov;283(5):C1501-10.

23.

Mechanism of thrombin-induced angiogenesis.

Maragoudakis ME, Tsopanoglou NE, Andriopoulou P.

Biochem Soc Trans. 2002 Apr;30(2):173-7. Review.

PMID:
12023846
24.

Effects of thrombin/thrombosis in angiogenesis and tumour progression.

Maragoudakis ME, Tsopanoglou NE, Andriopoulou P, Maragoudakis MM.

Matrix Biol. 2000 Aug;19(4):345-51. Review.

PMID:
10963995
25.

On the mechanism(s) of thrombin induced angiogenesis.

Maragoudakis ME, Tsopanoglou NE.

Adv Exp Med Biol. 2000;476:47-55.

PMID:
10949654
27.

Putrescine: a novel inhibitor of glycosylation-induced cross-links in laminin.

Tsopanoglou NE, Zioudrou C, Tsilibary EC, Charonis AS.

Microcirculation. 1995 Sep;2(3):283-7.

PMID:
8748952
28.

Validation of collagenous protein synthesis as an index for angiogenesis with the use of morphological methods.

Maragoudakis ME, Haralabopoulos GC, Tsopanoglou NE, Pipili-Synetos E.

Microvasc Res. 1995 Sep;50(2):215-22.

PMID:
8538501
29.

Opposing effects on modulation of angiogenesis by protein kinase C and cAMP-mediated pathways.

Tsopanoglou NE, Haralabopoulos GC, Maragoudakis ME.

J Vasc Res. 1994 Jul-Aug;31(4):195-204.

PMID:
7517701
30.

Leukotrienes C4 and D4 promote angiogenesis via a receptor-mediated interaction.

Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME.

Eur J Pharmacol. 1994 Jun 2;258(1-2):151-4.

PMID:
7523148
31.

Protein kinase C involvement in the regulation of angiogenesis.

Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME.

J Vasc Res. 1993 Jul-Aug;30(4):202-8.

PMID:
7689346
32.

Thrombin promotes angiogenesis by a mechanism independent of fibrin formation.

Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME.

Am J Physiol. 1993 May;264(5 Pt 1):C1302-7.

PMID:
7684562

Supplemental Content

Loading ...
Support Center